Margarida Maia, PhD,  science writer—

Pregnant women with high pressure in the pulmonary artery of the heart, but who are not considered at risk of pulmonary hypertension (PH), are likely to also be at lower risk of other major cardiac problems, researchers reported. In this study, the level of PH probability was judged based…

Levels of a protein found in certain blood cells indicate the severity and prognosis of pulmonary arterial hypertension (PAH), a study suggested. The findings could help achieve earlier diagnosis of PAH, which may improve clinical outcomes, researchers said. The study, “Circulating nerve growth factor receptor positive…

Claritas Pharmaceuticals has signed a letter of intent with the Salzman Group to acquire exclusive global rights to develop and market R-107 — a liquid form of nitric oxide — to treat, and possibly reverse, pulmonary arterial hypertension (PAH). The agreement is expected to come into effect by May…

United Therapeutics has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of Tyvaso DPI, a dry powder inhaled formulation of treprostinil, for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). To expedite the process, the company  applied…

More than three-quarters (76%) of adults with pulmonary arterial hypertension (PAH) being treated with Uptravi (selexipag) either saw no increase or a decline in their risk of death over one year, a study based real-world data reports. These findings — in nearly 500 people taking part in an…

Patients whose pulmonary hypertension is associated with chronic obstructive pulmonary disease (PH-COPD) have a worse clinical status and a poorer outcome than those with idiopathic pulmonary arterial hypertension (IPAH), a study based on real-world data from the COMPERA registry reports. Although PH is typically mild to moderate in COPD,…

Treatment with Acceleron Pharma’s sotatercept appears to be effective and generally well tolerated in people with pulmonary arterial hypertension (PAH), according to new data from the ongoing PULSAR and SPECTRA Phase 2 clinical trials. These data will be presented at the American Thoracic Society (ATS) 2021 International…

VeriSIM Life has opened PulmoSIM Therapeutics, its pharmaceutical subsidiary focused on developing treatments for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), before moving to other rare respiratory diseases. “We are thrilled to announce the launch of PulmoSIM as it demonstrates the indefinite capabilities of the VeriSIM’s…

Pulmonary hypertension (PH) occurs in 60% of children with the heart defect known as patent ductus arteriosus, with girls being more likely to develop PH than boys, a study found. A child with patent ductus arteriosus has an opening, or duct, between two major blood vessels leading from the…